Tesamorelin vs Substance P
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Tesamorelin
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH). It is FDA-approved under the brand name Egrifta for reducing excess abdominal fat in HIV-infected patients with lipodystrophy.
Full details →Substance P
Substance P is an 11-amino acid neuropeptide involved in pain transmission, inflammation, and various neurological processes. While not used therapeutically itself, understanding it is crucial for pain research.
Full details →Side-by-Side Comparison
| Aspect | Tesamorelin | Substance P |
|---|---|---|
| Mechanism | Stimulates the pituitary gland to produce and release growth hormone by binding to GHRH receptors. Increases IGF-1 levels which promotes lipolysis and reduces visceral adipose tissue. | Binds primarily to NK1 receptors to transmit pain signals from peripheral nerves to the CNS. Also promotes inflammation, causes vasodilation, and stimulates immune cells. |
| Typical Dosage | FDA-approved dose: 2mg administered subcutaneously once daily. Research protocols may use various dosing schedules. | Not used as a therapeutic agent. NK1 receptor antagonists (blocking Substance P) are used clinically for chemotherapy-induced nausea. |
| Administration | Subcutaneous injection into the abdomen. Rotate injection sites. Best administered at the same time daily, preferably in the evening. | Research compound only. Therapeutic applications focus on blocking rather than administering Substance P. |
| Side Effects | Common side effects include injection site reactions (erythema, pruritus), joint pain, peripheral edema, and muscle pain. May cause elevated blood glucose. | Administration would cause pain, inflammation, and neurogenic responses. Not given therapeutically. |
| Best For |